Optimising infliximab induction dosing for patients with ulcerative colitis-Reference-Cited by-同舟云学术

Optimising infliximab induction dosing for patients with ulcerative colitis

Published:2019-02-10 Issue:4 Volume:85 Page:782-795
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Dreesen Erwin¹^ORCID,Faelens Ruben²,Van Assche Gert³,Ferrante Marc³,Vermeire Séverine³,Gils Ann¹,Bouillon Thomas²

Affiliation:

1. Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological SciencesKU Leuven – University of Leuven Leuven Belgium

2. Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological SciencesKU Leuven – University of Leuven Leuven Belgium

3. Department of Gastroenterology and HepatologyUniversity Hospitals Leuven Leuven Belgium

Funder

Research Foundation - Flanders

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13859

Reference29 articles.

1. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

2. Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

3. Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis: Commentary;Seow C;Inflamm Bowel Dis Monit,2009

4. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

5. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease;Frontiers in Pharmacology;2024-08-27

2. Model-informed precision dosing: State of the art and future perspectives;Advanced Drug Delivery Reviews;2024-08

3. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

4. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

5. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease;Medicina;2024-01-31